Upregulation of HHLA2 was associated with poor clinical features and outcomes in breast cancer, clear cell renal cell carcinoma, colorectal cancer, and osteosarcoma, whereas downregulation of HHLA2 might be beneficial for gastric cancer and epithelial ovarian cancer [6, 7]. Here, HHLA2 is linked to osteosarcoma.